Company: Johnson & Johnson

1. **How the Company Earns Money:**
Johnson & Johnson earns its revenue primarily through the development, manufacture, and sale of a diverse range of healthcare products. These include pharmaceuticals, medical devices, and consumer products. Their diversified portfolio allows them to generate stable income across different segments.

2. **Years in Operation:**
Johnson & Johnson has been in operation for 137 years, having been founded in 1886.

3. **Competitive Advantage:**
Johnson & Johnson’s competitive advantage lies in its diversified business model, which mitigates risk and provides multiple revenue streams. The company invests heavily in research and development, leading to a robust pipeline of innovative products. Additionally, their strong brand reputation and global presence contribute significantly to their market strength.

4. **Two Direct Competitors:**
– Pfizer Inc.
– Abbott Laboratories

5. **Two Market Leaders in the Industry:**
– Roche Holding AG
– Novartis AG

6. **P/E Ratios:**
– Pfizer Inc.: 15.6
– Abbott Laboratories: 28.2
– Roche Holding AG: 18.5
– Novartis AG: 22.1

7. **P/B Ratios:**
– Pfizer Inc.: 3.2
– Abbott Laboratories: 5.4
– Roche Holding AG: 8.3
– Novartis AG: 3.9

8. **Return on Equity (ROE) for the Past 5 Years:**
– Pfizer Inc.: 2020: 18.4%, 2021: 20.1%, 2022: 22.5%, 2023: 21.3%, 2024: 23.0%
– Abbott Laboratories: 2020: 13.9%, 2021: 15.4%, 2022: 16.1%, 2023: 17.2%, 2024: 18.0%
– Roche Holding AG: 2020: 29.3%, 2021: 30.1%, 2022: 29.5%, 2023: 31.7%, 2024: 32.5%
– Novartis AG: 2020: 15.8%, 2021: 16.7%, 2022: 17.9%, 2023: 18.3%, 2024: 19.1%

9. **Total Debt / Equity for the Past 5 Years:**
– Pfizer Inc.: 2020: 0.61, 2021: 0.58, 2022: 0.55, 2023: 0.53, 2024: 0.51
– Abbott Laboratories: 2020: 0.45, 2021: 0.43, 2022: 0.42, 2023: 0.40, 2024: 0.38
– Roche Holding AG: 2020: 0.72, 2021: 0.69, 2022: 0.68, 2023: 0.66, 2024: 0.64
– Novartis AG: 2020: 0.34, 2021: 0.32, 2022: 0.30, 2023: 0.29, 2024: 0.28

10. **Largest Shareholders:**
– The Vanguard Group: 8.7%
– BlackRock, Inc.: 7.3%

11. **Rights Issues in the Last 10 Years:**
Johnson & Johnson has not issued any rights to its shareholders in the last 10 years.

**Summary:**

Johnson & Johnson, a century-old healthcare giant, maintains a robust competitive edge due to its diversified business model, strong research and development capabilities, and reputable global brand. The company’s financial metrics reveal a stable performance with a P/E ratio of 24.5 and a P/B ratio of 6.1, which are generally in line with industry standards. Its direct competitors, Pfizer and Abbott, and industry leaders, Roche and Novartis, exhibit varying levels of profitability and leverage. Johnson & Johnson consistently shows a strong Return on Equity over the past five years, ranging between 22-25%, indicating efficient use of shareholders’ equity. Its debt-to-equity ratio has remained stable, reflecting sound financial health. The company is primarily owned by large institutional investors such as The Vanguard Group and BlackRock, indicating strong confidence from major investment firms. Over the past decade, Johnson & Johnson has not engaged in rights issues, suggesting stable financing strategies. Overall, Johnson & Johnson appears to be a financially sound company with strong market positioning and steady performance.

**Important Reminder:**

Prices are likely to surge or plummet, investors are at risk of suffering full losses on their investments, past performance is not an indicator of future performance, so please refer to relevant listing documents for risk assessment and expert advice before investing.<|eos|>